BioWorld Asia

June 20, 2007

View Archived Issues

Diamyd Shares Fall On News Of Diabetes Trial Debacle

Diamyd Medical AB lost around 40 percent of its value Monday on news that it had to jettison a Phase II/III clinical trial of Diamyd, a therapeutic vaccine in development for treating autoimmune diabetes.(BioWorld International) Read More

Bill Limiting Hybrid Embryo Research Riles UK Scientists

Read More

Genomic Activity Study Produces Some Shockers

Read More

EU Trade Leader Delivers Strong Defense For Biotech

Read More

BioInvent Seeks Added Support, More Cash To Boost Pipeline

Read More

Start-Up Finds Peptide Fix For Annual Flu Vaccine Work

Read More

Other News To Note

Read More